Scantox, together with its majority owner Impilo, has finalised the acquisition of the CRO, Gentronix.
Gentronix is recognised within the industry for its genetic toxicology services, and will allow Scantox to expand its service offerings to support pre-IND enabling studies.
For 25 years, Gentronix has enabled the early identification of genotoxic compounds, while also supporting companies in their late-stage drug development initiatives with GLP studies.
The company offers a range of screening and regulatory genotoxicity assays and services, including the OECD 488 Big Blue Transgenic Mutation assay.
Post-acquisition, Gentronix wil continue to operate under its current name.
Scantox Group's CEO, Jeanet Løgsted, commented: "Gentronix´s service line, client base, high quality standards and — not least — people culture fits perfectly with our DNA. Our business plan is to continuously expand our service portfolio across all sites and add scientific excellence to the Group.”
Matt Tate, CEO of Gentronix, added: “Becoming a part of Scantox Group is a fantastic next step for Gentronix, opening up unique possibilities for us to offer an even greater service portfolio to our clients."
"As an organisation, we look forward to collaborating with our new colleagues and continuing to support the delivery of world-leading contract research services to our customers. There is a strong strategic rationale in teaming up with Scantox and we have identified multiple commercial synergies”.